Table 3. Univariable analyses of overall survival in all patients (n=250).
| Features | HR (95% CI) | P value |
|---|---|---|
| Age (>65 vs. ≤65 years) | 1.672 (1.138–2.455) | 0.009 |
| Sex (male vs. female) | 0.598 (0.385–0.928) | 0.02 |
| Treatment lines (3 or above vs. 1 or 2) | 1.509 (1.021–2.229) | 0.04 |
| Pathological staging (IV vs. I or II or III) | 1.253 (0.827–1.899) | 0.29 |
| Pathological type (SCLC vs. NSCLC) | 1.018 (0.612–1.694) | 0.95 |
| Tobacco use history (yes vs. no) | 0.931 (0.623–1.391) | 0.73 |
| Alcohol use history (yes vs. no) | 0.932 (0.618–1.407) | 0.74 |
| RBC | 0.726 (0.550–0.958) | 0.02 |
| ALB | 0.964 (0.935–0.995) | 0.02 |
| BASO% | 0.466 (0.201–1.082) | 0.08 |
| EO% | 0.948 (0.834–1.077) | 0.41 |
HR, hazard ratio; CI, confidence interval; SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; RBC, red blood cell; ALB, albumin; BASO%, percentage of basophil cell; EO%, percentage of acidophilic cell.